Marcela Osorio1, Sami P Moubayed1,2, Henry Su1, Mark L Urken1,2. 1. Thyroid, Head and Neck Cancer (THANC) Foundation, New York, New York. 2. Department of Otolaryngology - Head and Neck Surgery, Mount Sinai Beth Israel, New York, New York.
Abstract
BACKGROUND: Thyroid cancer is the fastest growing cancer in the United States. A small portion of differentiated thyroid cancers (DTCs; 2% to 13%) develop bone metastases, which can decrease a patient's survival rate by more than 60%. METHODS: A systematic literature search of studies, including patients with DTC with bone metastases, was conducted by following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A case series of patients with DTC diagnosed with bone metastases seen at our institution was also included. RESULTS: A total of 616 bone metastases sites in 317 patients were identified in 14 case series. Ten patients were identified in our institutional case series. The most common sites of metastases are spine (34.6%), pelvis (25.5%), sternum and ribs (18.3%), extremities (10.2%), shoulder girdle (5.4%), and craniomaxillofacial (5.4%). CONCLUSION: The axial skeleton is the primary target of bone metastases in DTC. The relative distribution of bone metastases and red marrow content follow a similar rank.
BACKGROUND:Thyroid cancer is the fastest growing cancer in the United States. A small portion of differentiated thyroid cancers (DTCs; 2% to 13%) develop bone metastases, which can decrease a patient's survival rate by more than 60%. METHODS: A systematic literature search of studies, including patients with DTC with bone metastases, was conducted by following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A case series of patients with DTC diagnosed with bone metastases seen at our institution was also included. RESULTS: A total of 616 bone metastases sites in 317 patients were identified in 14 case series. Ten patients were identified in our institutional case series. The most common sites of metastases are spine (34.6%), pelvis (25.5%), sternum and ribs (18.3%), extremities (10.2%), shoulder girdle (5.4%), and craniomaxillofacial (5.4%). CONCLUSION: The axial skeleton is the primary target of bone metastases in DTC. The relative distribution of bone metastases and red marrow content follow a similar rank.
Authors: Nicholas J Szerlip; Alexandra Calinescu; Eleanor Smith; Rebecca Tagett; Katrina L Clines; Henry H Moon; Russell S Taichman; Catherine H Van Poznak; Gregory A Clines Journal: Neurosurgery Date: 2018-12-01 Impact factor: 4.654
Authors: Suwardjo Suwardjo; Widya Surya Avanti; Ery Kus Dwianingsih; Wirsma Arif Harahap; Sumadi Lukman Anwar Journal: Ann Med Surg (Lond) Date: 2020-11-28
Authors: M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti Journal: J Endocrinol Invest Date: 2020-07-21 Impact factor: 4.256
Authors: Arnaud Jannin; Livia Lamartina; Coralie Moutarde; Mehdi Djennaoui; George Lion; Benjamin Chevalier; Marie Christine Vantyghem; Frédéric Deschamps; Julien Hadoux; Eric Baudin; Martin Schlumberger; Sophie Leboulleux; Christine Do Cao Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-12 Impact factor: 10.057
Authors: A Nervo; A Ragni; F Retta; M Gallo; A Piovesan; V Liberini; M Gatti; U Ricardi; D Deandreis; E Arvat Journal: J Endocrinol Invest Date: 2020-08-03 Impact factor: 4.256